CN110693035A - 一种供骨质疏松人群食用的含肽组合物及应用 - Google Patents
一种供骨质疏松人群食用的含肽组合物及应用 Download PDFInfo
- Publication number
- CN110693035A CN110693035A CN201911061557.5A CN201911061557A CN110693035A CN 110693035 A CN110693035 A CN 110693035A CN 201911061557 A CN201911061557 A CN 201911061557A CN 110693035 A CN110693035 A CN 110693035A
- Authority
- CN
- China
- Prior art keywords
- peptide
- powder
- containing composition
- osteoporosis
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 50
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 45
- 241000283074 Equus asinus Species 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 18
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 18
- 241000283690 Bos taurus Species 0.000 claims abstract description 15
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims abstract description 13
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 13
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 13
- 241000219781 Pueraria montana var. lobata Species 0.000 claims abstract description 13
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 13
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 13
- 229940034055 calcium aspartate Drugs 0.000 claims abstract description 13
- 239000005018 casein Substances 0.000 claims abstract description 13
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000021240 caseins Nutrition 0.000 claims abstract description 13
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 13
- 239000011710 vitamin D Substances 0.000 claims abstract description 13
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 13
- 229940046008 vitamin d Drugs 0.000 claims abstract description 13
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 210000000963 osteoblast Anatomy 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 210000002435 tendon Anatomy 0.000 abstract description 2
- 206010017076 Fracture Diseases 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010010214 Compression fracture Diseases 0.000 description 2
- 206010039984 Senile osteoporosis Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010058907 Spinal deformity Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于保健食品、功能性食品技术领域,具体涉及一种供骨质疏松人群食用的含肽组合物及其应用。本发明所述组合物以牛骨低聚肽粉、驴骨胶原蛋白肽粉、葛根粉为主要成分,辅以天门冬酸钙、酪蛋白磷酸肽、维生素D等制备成一种供骨质疏松人群食用的含肽组合物,所述组合物具有强筋健骨、促进成骨细胞增值的功效,改善骨质疏松的效果显著,可用于制备辅助改善骨质疏松的产品。
Description
技术领域
本发明属于保健食品、功能性食品技术领域,具体涉及一种供骨质疏松人群食用的含肽组合物及其应用。
背景技术
骨质疏松即骨质疏松症,是多种原因引起的一组骨病,骨组织有正常的钙化,钙盐与基质呈正常比例,以单位体积内骨组织量减少为特点的代谢性骨病变。骨质疏松症可发生于不同性别和任何年龄,但多见于绝经后女性和老年男性。骨质疏松症分为原发性和继发性二大类。原发性骨质疏松症又分为绝经后骨质疏松症(Ⅰ型)、老年性骨质疏松症(Ⅱ型)和特发性骨质疏松(包括青少年型)三种。绝经后骨质疏松症一般发生在妇女绝经后5~10年内;老年性骨质疏松症一般指老人70岁后发生的骨质疏松;而特发性骨质疏松主要发生在青少年,病因尚不明。骨质疏松症除了主要与绝经和老年有关的原发性骨质疏松外,还可能由多种疾病引起,称为继发性骨质疏松症。
骨质疏松症本身包括三大类症状:(1)疼痛患者可有腰背酸痛或周身酸痛,负荷增加时疼痛加重或活动受限,严重时翻身、起坐及行走有困难;(2)脊柱变形骨质疏松严重者可有身高缩短和驼背。椎体压缩性骨折会导致胸廓畸形,腹部受压,影响心肺功能等;(3)骨折非外伤或轻微外伤发生的骨折为脆性骨折,是低能量或非暴力骨折,如从站高或小于站高跌倒或因其他日常活动而发生的骨折。发生脆性骨折的常见部位为胸、腰椎、髋部、桡、尺骨远端和肱骨近端。骨质疏松造成的疼痛本身可降低患者的生活质量,脊柱变形、骨折可致残,使患者活动受限、生活不能自理,增加肺部感染、褥疮发生率,不仅患者生命质量和死亡率增加也给个人、家庭和社会带来沉重的经济负担。
目前对骨质疏松症的治疗仅增加富含钙、蛋白质的营养物质、骨健康补充剂的摄入、适当运动是远远不够的,需根据患者情况加用药物。有效的药物治疗能阻止和治疗骨质疏松症,包括雌激素代替疗法、降钙素、选择性雌激素受体调节剂以及二磷酸盐,但这些药物可以阻止骨吸收但对骨形成的作用特别小,而且可能带来其他系统的不良反应。
发明内容
有鉴于此,本发明的目的在于针对现有技术中存在的问题,提供一种供骨质疏松人群食用的含肽组合物及其应用。
为实现本发明的目的,本发明采用如下技术方案:
一种供骨质疏松人群食用的含肽组合物,由牛骨低聚肽粉、驴骨胶原蛋白肽粉、葛根粉组成。
作为优选,以重量份计,牛骨低聚肽粉3份-4份、驴骨胶原蛋白肽粉3份-4份、葛根粉1份-2份。
进一步的,在一些实施方案中,所述含肽组合物还包括辅料。
其中,所述辅料为天门冬氨酸钙、酪蛋白磷酸肽和维生素D。
作为优选,以重量份计,天门冬氨酸钙0.01份-0.5份、酪蛋白磷酸肽0.01份-0.5份、维生素D 0.5份-1份。
在一些实施方案中,以重量份计,所述含肽组合物由牛骨低聚肽粉3份、驴骨胶原蛋白肽粉4份、葛根粉1份、天门冬氨酸钙0.5份、酪蛋白磷酸肽0.01份、维生素D1份组成。
在一些实施方案中,以重量份计,所述含肽组合物由牛骨低聚肽粉4份、驴骨胶原蛋白肽粉3份、葛根粉2份、天门冬氨酸钙0.01份、酪蛋白磷酸肽0.5份、维生素D 0.5份组成。
在一些实施方案中,以重量份计,所述含肽组合物由牛骨低聚肽粉3份、驴骨胶原蛋白肽粉3份、葛根粉2份、天门冬氨酸钙0.5份、酪蛋白磷酸肽0.5份、维生素D 0.5份组成。
在一些实施方案中,以重量份计,所述含肽组合物由牛骨低聚肽粉4份、驴骨胶原蛋白肽粉4份、葛根粉1份、天门冬氨酸钙0.01份、酪蛋白磷酸肽0.01份、维生素D 0.5份组成。
本发明所述含肽组合物中的各成分均可以通过商业渠道购买得到。
在一些实施方案中,所述牛骨低聚肽粉由以下制备方法制备获得:以新鲜牛骨为原料,依次经破碎、清洗、高压提取、复合蛋白酶酶解、过滤、浓缩工艺加工,添加或不添加食品添加剂柠檬酸、食品用香精,经混合、干燥,制作而成牛骨低聚肽粉。
在一些实施方案中,所述驴骨胶原蛋白肽粉由以下制备方法制备获得:
以鲜驴骨为原料,经高压提取、食品添加剂复合酶酶解、过滤、浓缩、干燥,制作而成驴骨胶原蛋白肽粉。
本发明所述组合物具有强筋健骨、促进成骨细胞增值、改善骨质疏松的功效,因此本发明提供了所述组合物在制备辅助改善骨质疏松产品中的应用。
本发明所述组合物以牛骨低聚肽粉、驴骨胶原蛋白肽粉、葛根粉为主要成分,辅以辅料制备成一种供骨质疏松人群食用的含肽组合物,所述组合物具有强筋健骨、促进成骨细胞增值的功效,改善骨质疏松的效果显著,可用于制备辅助改善骨质疏松的产品。
具体实施方式
本发明公开了一种供骨质疏松人群食用的含肽组合物及其应用。本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及产品已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法进行改动或适当变更与组合,来实现和应用本发明技术。
为了进一步理解本发明,下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
如无特殊说明,本发明实施例中所涉及的试剂均为市售产品,均可以通过商业渠道购买获得。
实施例1:本发明所述含肽组合物
由牛骨低聚肽粉3份、驴骨胶原蛋白肽粉4份、葛根粉1份、天门冬氨酸钙0.5份、酪蛋白磷酸肽0.01份、维生素D1份混合组成。
实施例2:本发明所述含肽组合物
由牛骨低聚肽粉4份、驴骨胶原蛋白肽粉3份、葛根粉2份、天门冬氨酸钙0.01份、酪蛋白磷酸肽0.5份、维生素D 0.5份混合组成。
实施例3:本发明所述含肽组合物
由牛骨低聚肽粉3份、驴骨胶原蛋白肽粉3份、葛根粉2份、天门冬氨酸钙0.5份、酪蛋白磷酸肽0.5份、维生素D 0.5份混合组成。
实施例4:本发明所述含肽组合物
由牛骨低聚肽粉4份、驴骨胶原蛋白肽粉4份、葛根粉1份、天门冬氨酸钙0.01份、酪蛋白磷酸肽0.01份、维生素D 0.5份混合组成。
试验例:
1、临床实验观察:
本发明对300例患者进行临床观察,患者为男女各年龄段,均为骨质疏松相关疾病,表现为胸、腰椎压缩性骨折,脊椎后弯,胸廓畸形等。服用方法:口服本发明实施例1的含肽组合物,一日两至三次,连续服用二个月至半年。
其中,评定标准:
治愈:骨质疏松的临床表现消失,功能活动恢复正常,经检查各项指标逐步恢复正常。
好转:骨质疏松的临床表现明显好转或好转,经检查各项指标略有好转。
无效:骨质疏松的临床表现没有改善,未见好转。
效果:服用本发明所述含肽组合物有效率94.5%,治愈率43.5%,好转率51%,无效5.5%。
本发明实施例2-4所述的含肽组合物效果与实施例1所述含肽组合物效果相当,有效率>90%。
2、典型案例
李女士,30多岁,患类风湿,骨关节疼、膝盖疼,关节疼痛无法睡眠,人消瘦。服用实施例1所述含肽组合物半年后,风湿关节痛减轻,体重增加,皮肤也有所改善。
刘女士,50多岁,15年发现患有腰椎间盘突出症,服用实施例1所述含肽组合物半年后,腰部疼痛明显减轻。
上述实施例的说明只是用于理解本发明的方法及其核心思想。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也将落入本发明权利要求的保护范围内。
Claims (8)
1.一种供骨质疏松人群食用的含肽组合物,其特征在于,由牛骨低聚肽粉、驴骨胶原蛋白肽粉、葛根粉组成。
2.根据权利要求1所述含肽组合物,其特征在于,以重量份计,牛骨低聚肽粉3份-4份、驴骨胶原蛋白肽粉3份-4份、葛根粉1份-2份。
3.根据权利要求1或2所述含肽组合物,其特征在于,还包括辅料。
4.根据权利要求3所述含肽组合物,其特征在于,所述辅料为天门冬氨酸钙、酪蛋白磷酸肽和维生素D。
5.根据权利要求4所述含肽组合物,其特征在于,以重量份计,天门冬氨酸钙0.01份-0.5份、酪蛋白磷酸肽0.01份-0.5份、维生素D 0.5份-1份。
6.根据权利要求1所述含肽组合物,其特征在于,所述牛骨低聚肽粉由以下制备方法制备获得:
以新鲜牛骨为原料,依次经破碎、清洗、高压提取、复合蛋白酶酶解、过滤、浓缩工艺加工,添加或不添加食品添加剂柠檬酸、食品用香精,经混合、干燥,制作而成牛骨低聚肽粉。
7.根据权利要求1所述含肽组合物,其特征在于,所述驴骨胶原蛋白肽粉由以下制备方法制备获得:
以鲜驴骨为原料,经高压提取、食品添加剂复合酶酶解、过滤、浓缩、干燥,制作而成驴骨胶原蛋白肽粉。
8.权利要求1-7任意一项所述含肽组合物在制备辅助改善骨质疏松的产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911061557.5A CN110693035A (zh) | 2019-11-01 | 2019-11-01 | 一种供骨质疏松人群食用的含肽组合物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911061557.5A CN110693035A (zh) | 2019-11-01 | 2019-11-01 | 一种供骨质疏松人群食用的含肽组合物及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110693035A true CN110693035A (zh) | 2020-01-17 |
Family
ID=69203333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911061557.5A Pending CN110693035A (zh) | 2019-11-01 | 2019-11-01 | 一种供骨质疏松人群食用的含肽组合物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110693035A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113261671A (zh) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | 一种用于预防和改善骨质疏松的牛骨肽组合物及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496576A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供骨伤患者食用含短肽的特殊膳食用食品配方 |
CN105669830A (zh) * | 2015-12-15 | 2016-06-15 | 北京天肽生物科技有限公司 | 一种复合低聚肽粉 |
CN106135890A (zh) * | 2015-04-14 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | 一种有助于骨关节健康的营养组合物 |
CN107753928A (zh) * | 2017-11-20 | 2018-03-06 | 中食都庆(山东)生物技术有限公司 | 一种具有增加骨密度功能的复方产品及其制备方法 |
CN108770989A (zh) * | 2018-06-21 | 2018-11-09 | 石丰 | 一种具有预防骨质疏松作用的牛骨胶原蛋白肽的制备方法 |
CN109601861A (zh) * | 2018-12-04 | 2019-04-12 | 沈阳师范大学 | 一种预防骨质疏松的全谷物营养粉及其制备方法 |
CN110074250A (zh) * | 2019-03-29 | 2019-08-02 | 广东澳思瑞雅健康美容生物科技有限公司 | 一种补充骨骼营养和改善骨骼功能的配方及制备方法 |
JP2019136035A (ja) * | 2018-02-09 | 2019-08-22 | 株式会社ユーグレナ | 骨密度改善用食品組成物、骨密度改善剤、前駆骨芽細胞増殖用食品組成物、骨分化促進用食品組成物、骨強化用食品組成物、抗骨粗鬆症用食品組成物、前駆骨芽細胞増殖剤、骨分化促進剤、骨強化剤、抗骨粗鬆症剤、骨密度改善剤の製造方法、前駆骨芽細胞増殖剤の製造方法、骨分化促進剤の製造方法、骨強化剤の製造方法及び抗骨粗鬆症剤の製造方法 |
-
2019
- 2019-11-01 CN CN201911061557.5A patent/CN110693035A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101496576A (zh) * | 2008-01-28 | 2009-08-05 | 中国食品发酵工业研究院 | 一种供骨伤患者食用含短肽的特殊膳食用食品配方 |
CN106135890A (zh) * | 2015-04-14 | 2016-11-23 | 青岛贝尔特生物科技有限公司 | 一种有助于骨关节健康的营养组合物 |
CN105669830A (zh) * | 2015-12-15 | 2016-06-15 | 北京天肽生物科技有限公司 | 一种复合低聚肽粉 |
CN107753928A (zh) * | 2017-11-20 | 2018-03-06 | 中食都庆(山东)生物技术有限公司 | 一种具有增加骨密度功能的复方产品及其制备方法 |
JP2019136035A (ja) * | 2018-02-09 | 2019-08-22 | 株式会社ユーグレナ | 骨密度改善用食品組成物、骨密度改善剤、前駆骨芽細胞増殖用食品組成物、骨分化促進用食品組成物、骨強化用食品組成物、抗骨粗鬆症用食品組成物、前駆骨芽細胞増殖剤、骨分化促進剤、骨強化剤、抗骨粗鬆症剤、骨密度改善剤の製造方法、前駆骨芽細胞増殖剤の製造方法、骨分化促進剤の製造方法、骨強化剤の製造方法及び抗骨粗鬆症剤の製造方法 |
CN108770989A (zh) * | 2018-06-21 | 2018-11-09 | 石丰 | 一种具有预防骨质疏松作用的牛骨胶原蛋白肽的制备方法 |
CN109601861A (zh) * | 2018-12-04 | 2019-04-12 | 沈阳师范大学 | 一种预防骨质疏松的全谷物营养粉及其制备方法 |
CN110074250A (zh) * | 2019-03-29 | 2019-08-02 | 广东澳思瑞雅健康美容生物科技有限公司 | 一种补充骨骼营养和改善骨骼功能的配方及制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113261671A (zh) * | 2021-05-27 | 2021-08-17 | 杭州佰倍优生物科技有限公司 | 一种用于预防和改善骨质疏松的牛骨肽组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101966222A (zh) | 一种具有壮骨功效的药物组合物、制剂及其制备方法 | |
CN103721242A (zh) | 一种药物组合物在预防或治疗骨质疏松中的新用途 | |
US10758580B2 (en) | Composition of sea buckthorn pulp oil and panax notoginseng saponins for treating osteoporotic fracture and/or osteoarthritis and uses thereof | |
CN107349333B (zh) | 具有增加骨密度功效的组合物及其制备方法和应用 | |
CN105816469B (zh) | 20(R)-人参皂苷Rg3在制备用于治疗骨质疏松症的药物或保健品中的应用及药物 | |
CN109453342A (zh) | 一种具有关节保护功效的中药组合物及应用、制备方法、保健食品 | |
CN113261671A (zh) | 一种用于预防和改善骨质疏松的牛骨肽组合物及其应用 | |
CN110693035A (zh) | 一种供骨质疏松人群食用的含肽组合物及应用 | |
CN107372835A (zh) | 一种增加骨密度促进骨健康的保健营养咀嚼奶片及其制备方法 | |
CN108938989B (zh) | 一种治疗骨质疏松症的覆茴精健骨散 | |
CN110859904A (zh) | 一种可补肾助阳、益气生精的芡实口服液 | |
CN1332676C (zh) | 补钙制剂及制备方法 | |
KR20060093918A (ko) | 숙지황과 오가피의 혼합 생약재 추출물 및 이를 유효성분으로 하는 골다공증 예방 및 치료용 조성물 | |
CN108888751B (zh) | 一种用于治疗和预防关节炎的组合物及其制备方法 | |
CN104587456A (zh) | 一种增加骨密度的保健品的制作工艺 | |
CN101804075A (zh) | 海星在制备治疗骨质疏松症的药物中的应用 | |
KR20170096758A (ko) | 두개골 골절 회복에 효능이 있는 가미십전대보 조성물 | |
CN105477504A (zh) | 一种用于治疗原发性骨质疏松症的药物 | |
KR20170055354A (ko) | 인삼 추출물, 작약 추출물, 감초 추출물 및 키토산을 유효성분으로 포함하는 폐경 또는 난소절제로 인한 여성 골다공증 예방 또는 치료용 약학적 조성물 | |
CN1270741C (zh) | 补骨丸 | |
CN114558088B (zh) | 一种治疗原发性骨质疏松症的蒙药复方及其应用 | |
CN102631496B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN103191315A (zh) | 一种治疗绝经后骨质疏松症的中药 | |
CN108310206B (zh) | 一种用于预防或治疗骨质疏松症的中药组合物及其制备方法和应用 | |
CN106974992A (zh) | 一种增加骨密度的组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200117 |
|
RJ01 | Rejection of invention patent application after publication |